Somatropin biosimilar - Amega Biotech

Drug Profile

Somatropin biosimilar - Amega Biotech

Alternative Names: recombinant human growth hormone - Amega Biotech

Latest Information Update: 15 Aug 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amega Biotech
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Growth disorders; Short stature; Somatotropin deficiency

Most Recent Events

  • 15 Aug 2013 Investigation in Growth disorders in Argentina (Parenteral)
  • 15 Aug 2013 Investigation in Short stature in Argentina (Parenteral)
  • 15 Aug 2013 Investigation in Somatotropin deficiency in Argentina (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top